User profiles for Susanna Dunachie
 | Susanna DunachieNIHR Global Research Professor, University of Oxford Verified email at ndm.ox.ac.uk Cited by 44416 |
[HTML][HTML] Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
…, M De Luca, K Dokova, A Dramowski, SJ Dunachie… - The lancet, 2022 - thelancet.com
Background Antimicrobial resistance (AMR) poses a major threat to human health around
the world. Previous publications have estimated the effect of AMR on incidence, deaths, …
the world. Previous publications have estimated the effect of AMR on incidence, deaths, …
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
…, J Drake, R Drake-Brockman, RE Drury, SJ Dunachie… - The Lancet, 2020 - thelancet.com
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
[PDF][PDF] Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA.1 …
rapidly to become globally dominant and has split into a number of sublineages. BA.1 …
[HTML][HTML] Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
began when the first sequence was published, and this forms the basis for …
began when the first sequence was published, and this forms the basis for …
[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
[PDF][PDF] Antibody evasion by the P. 1 strain of SARS-CoV-2
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. …
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. …
[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera
…, S Charlton, TS Walter, E Barnes, SJ Dunachie… - Cell, 2021 - cell.com
SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being
deployed at scale, aiming to generate responses against the virus spike. The scale of the …
deployed at scale, aiming to generate responses against the virus spike. The scale of the …
[PDF][PDF] Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was
introduced in the United Kingdom to accelerate population coverage with a single dose. At this …
introduced in the United Kingdom to accelerate population coverage with a single dose. At this …
